Treatment of vulvar and vaginal atrophy: clinical experience with ospemifene

Guest Editor: Santiago Palacios, Palacios’ Institute of Women’s Health, Madrid, Spain

This Special Issue contains case studies about the experiences of women with vulvar and vaginal atrophy during treatment with ospemifene. It covers the effects of ospemifene on bone markers, its use in breast cancer survivors, and in women with dyslipidemia, urinary incontinence or VVA-related sexual dysfunction, and its concomitant use with laser therapy.

List of articles

Ospemifene for vulvar and vaginal atrophy: an overview

Santiago Palacios MD, PhD

Experience with ospemifene in patients with vulvar and vaginal atrophy: case studies with bone marker profiles

María del Carmen Pingarrón Santofimia MD, Silvia Pilar González Rodríguez MD, PhD, Mariella Lilue MD, Santiago Palacios MD, PhD

Experience with ospemifene in patients with vulvar and vaginal atrophy and a history of breast cancer: case studies

Mariella Lilue MD, Santiago Palacios MD, PhD, María del Carmen Pingarrón Santofimia MD

Experience with ospemifene in a patient with vulvovaginal atrophy and dyslipidemia: a case study

Silvia Pilar González Rodríguez MD, PhD

Experience with ospemifene in patients with vulvar and vaginal atrophy and urinary incontinence: case studies

Zuramis Estrada Blanco MD, Mariella Lilue MD, Santiago Palacios MD, PhD

Experience with ospemifene in patients with vulvovaginal atrophy treated with laser therapy: case studies

Félix Lugo Salcedo MD, Zuramis Estrada Blanco MD

Experience with ospemifene in patients with vulvar and vaginal atrophy and associated sexual dysfunction: case studies

Ana Rosa Jurado López MD, PhD, Francisca Molero Rodríguez MD